Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Curasight: Video præsentation af Q3 2025 regnskabsevent

By Michael FriisHead of Equities
Curasight

Hvis du ikke deltog i eventet i går, eller gerne vil se præsentationen igen med Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær, kan du se hele præsentationen her: 

Curasight Q3 2025 regnskabsevent

Fokus på eventet var rettet mod den seneste nyhedsstrøm for både uTRACE® og uTREAT® – samt hvad man kan forvente af nyheder i den kommende tid fra pipelinen.

Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR abonnementsaftale/Michael Friis 02/12-2025 - kl. 10:02.

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.